FDA Approves First Gene Therapy for Wiskott-Aldrich Syndrome — A Major Milestone for Rare Disease Treatment

The U.S. Food and Drug Administration recently approved the first-ever gene therapy for Wiskott-Aldrich syndrome (WAS) — a rare, life-threatening genetic immune disorder. While this treatment is not for vision loss, the significance of this decision reaches far beyond a single disease. For the broader rare disease community — including families affected by Bardet-Biedl Syndrome (BBS), retinitis pigmentosa (RP), and inherited retinal diseases (IRDs) — this approval represents something powerful: proof that gene therapy can move from research to reality. What Is Wiskott-Aldrich Syndrome? Wiskott-Aldrich syndrome is a rare genetic condition that primarily affects the immune system and blood clotting. It is caused by mutations in the WAS gene and often presents in early childhood. Without treatment, patients face serious infections, autoimmune complications, and increased risk of cancer. Until now, treatment options were extremely limited — typically requiring bone marrow transplantation, which carries significant risks and is not available to all patients. What Makes This FDA Approval H